Epidemiology and modern strategies for treating ischemic heart disease in patients with type 2 diabetes mellitus

• Andrey N. Bogomolov
• Kirill L. Kozlov
• Olga N. Kurochkina

Abstract

Diabetes mellitus is one of the main factors of early development and accelerated progression of atherosclerosis, including in the coronary arteries, which increases the risk of cardiovascular diseases and mortality from all causes. The review analyzes the literature data on the epidemiology of coronary heart disease and diabetes mellitus, presents modern methods of treating patients with a combination of coronary heart disease and type 2 diabetes, describes in detail hypoglycemic drugs with proven efficacy, benefit and/or safety for the cardiovascular system, gives characteristics and criteria for choosing reperfusion interventions in this category of patients.

Keywords: epidemiology; coronary heart disease; diabetes mellitus; sodium-glucose cotransporter type 2 inhibitors; glucagon-like peptide 1 receptor antagonists; chronic kidney disease; coronary artery bypass grafting; X-ray endovascular interventions, coronary artery stenting

References

1. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020; 25 (11): 201–50. DOI: https://doi.org/10.15829/29/1560-4071-2020-4076 (in Russian)
2. Emerging Risk Factors Collaboration; Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215–22.
3. Newman J.D., Anthopolos R., Mancini G.B.J., et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation. 2021; 144 (17): 1380–95. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.054439
4. Kurochkina O.N., Korotkov D.A., Bogomolov A.N., Kozlov K.L., Boltunov K.S. Long-term prognosis of adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary interventions. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2023; 11 (4): 7–12. DOI: https://doi.org/10.33029/2309-1908-2023-11-3-7-12 (in Russian)
5. Yuan T., Yang T., Chen H., Fu D., Hu Y., Wang J., et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019; 20: 247–60.
6. Bates E.R. Antiplatelet therapy in patients with coronary disease and type 2 diabetes. N Engl J Med. 2019; 381 (14): 1373–5. DOI: https://doi.org/10.1056/NEJMe1910813
7. Kurochkina O.N., Kerimova S.N., Ismailov Z.B., Yagupova T.A. Evaluation of the dynamics of glomerular filtration rate in patients with chronic kidney disease according to the regional registry. Klinicheskaya nefrologiya [Clinical Nephrology]. 2022; (2): 9–18. DOI: https://doi.org/10.18565/nephrology.2022.2.9-18 (in Russian)
8. Kurochkina О.N. Regional features of chronic kidney disease in the Komi Republic according to the register of the republican hospital. Nefrologiya i dializ [Nephrology and Dialysis]. 2020; 22 (2): 210–20. DOI: https://doi.org/10.28996/2618-9801-2020-2-210-220 (in Russian)
9. Kurochkina O.N. Features of chronic kidney disease in elderly patients. Uspekhi gerontologii [Advances of Gerontology]. 2020; 33 (6): 113–20. DOI: https://doi.org/10.34922/AE.2020.33.1.015 (in Russian)
10. Swamy S., Noor S.M., Mathew R.O. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023; 12 (22): 6984. DOI: https://doi.org/10.3390/jcm12226984
11. Samorodskaya I.V., Bubnova M.G., Akulova O.A., Drapkina O.M. Male and female mortality rates due to acute types of coronary artery disease in five-year age groups in the Russian Federation: what do the numbers mean? Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2022; 21 (12): 78–88. DOI: https://doi.org/10.15829/1728-8800-2022-3460 (in Russian)
12. Tolpygina S.N., Martsevich S. Yu. Investigation of CHD prognosis: new long-term follow-up data. Profilakticheskaya meditsina [Preventive Medicine]. 2016; (1): 30–6. DOI: https://doi.org/10.17116/profmed201619130-36 (in Russian)
13. Federal Register of patients with Diabetes Mellitus of the National Research Center of the Russian Federation FSBI «NMIC of Endocrinology» of the Ministry of Health of the Russian Federation. URL: https://sd.diaregistry.ru/ (in Russian)
14. Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2): 104–23. DOI: https://doi.org/10.14341/DM13035 (in Russian)
15. Marx N., Federici M., Schütt K., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44 (39): 4043–140. DOI: https://doi.org/10.1093/eurheartj/ehad192
16. Arnett D.K., Blumenthal R.S., Albert M.A., et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: 596–646. DOI: https://doi.org/10.1161/CIR.0000000000000678
17. Colberg S.R., Sigal R.J., Yardley J.E., et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016; 39: 2065–79. DOI: https://doi.org/10.2337/dc16-1728
18. Evert A.B., Dennison M., Gardner C.D., et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019; 42 (5): 731–54. DOI: https://doi.org/10.2337/dci19-0014
19. American Diabetes Association. Standards of Medical Care in Diabetes – 2022. Diabetes Care. 2022; 45 (suppl 1): S 1–2. DOI: https://doi.org/10.2337/dc22-Sint
20. Connolly S.J., Eikelboom J.W., Bosch J., et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an inter-national, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391: 205–18. DOI: https://doi.org/10.1016/S0140-6736(17)32458-3
21. Tsujimoto T., Kajio H., Shapiro M.F., et al. Risk of all-cause mortality in diabetic patients taking beta-blockers. Mayo Clin Proc. 2018; 93: 409–18. DOI: https://doi.org/10.1016/j.mayocp.2017.11.019
22. Standards of specialized diabetes care. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 11th ed. Moscow, 2023. DOI: https://doi.org/10.14341/DM13042 (in Russian)
23. Lim S., Kim K.M., Nauck M.A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab. 2018; 29 (4): 238–48. DOI: https://doi.org/10.1016/j.tem.2018.01.011
24. Marso S.P., Poulter N.R., Nissen S.E., et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013; 166 (5): 823–30.e5. DOI: https://doi.org/10.1016/j.ahj.2013.07.012
25. Leiter L.A., Bain S.C., Hramiak I., et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019; 18: 73. DOI: https://doi.org/10.1186/s12933-019-0871-8
26. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394 (10 193): 121–30. DOI: https://doi.org/10.1016/S0140-6736(19)31149-3
27. Green J.B., Hernandez A.F., D’Agostino R.B., et al. HARMONY Outcomes: a randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus – rationale, design, and baseline characteristics. Am Heart J. 2018; 203: 30–8. DOI: https://doi.org/10.1016/j.ahj.2018.03.030
28. Sattar N., Lee M.M., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9: 653–62. DOI: https://doi.org/10.1016/S2213-8587(21)00203-5
29. Ferrannini G., Hach T., Crowe S., et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38: 1730–5. DOI: https://doi.org/10.2337/dc15-0355
30. Al Jobori H., Daniele G., Adams J., et al. Empagliflozin treatment is associated with improved β-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2018; 103: 1402–7. DOI: https://doi.org/10.1210/jc.2017-01838
31. Tanaka S., Sugiura Y., Saito H., et al. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int. 2018; 94: 912–25. DOI: https://doi.org/10.1016/j.kint.2018.04.025
32. He L., Ma S., Zuo Q., et al. An effective sodium-dependent glucose transporter 2 inhibition, canagliflozin, prevents development of hypertensive heart failure in Dahl salt-sensitive rats. Front Pharmacol. 2022; 13: 856386. DOI: https://doi.org/10.3389/fphar.2022.856386
33. Aragón-Herrera A., Feijóo-Bandín S., Otero Santiago M., et al. Empagliflozin reduces the levels of CD 36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 2019; 170: 113677. DOI: https://doi.org/10.1016/j.bcp.2019.113677
34. Kogot-Levin A., Hinden L., Riahi Y., et al. Proximal tubule mTORC 1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors. Cell Rep. 2020; 32: 107954. DOI: https://doi.org/10.1016/j.celrep.2020.107954
35. Kurochkina O.N., Korotkov D.A., Sazhina A.S., Bogomolov A.N. Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect. Ratsional’naya farmakoterapiya v kardiologii [Rational Pharmacotherapy in Cardiology]. 2024; 20 (2): 258–64. DOI: https://doi.org/10.20996/1819-6446-2024-3014 EDN UZLJIY 9. (in Russian)
36. Fitchett D., Zinman B., Wanner C., et al.; EMPA-REG OUTCOME Trial Investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016; 37: 1526–34. DOI: https://doi.org/10.1093/eurheartj/ehv728
37. Neal B., Perkovic V., Mahaffey K.W., et al.; CANVAS Program Collaborative Group. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab. 2017; 19 (7): 926–35. DOI: https://doi.org/10.1111/dom.12924
38. Wiviott S.D., Raz I., Bonaca M.P., et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380: 347–57. DOI: https://doi.org/10.1056/NEJMoa1812389
39. Cosentino F., Cannon Ch., Cherney D.Z., et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020; 142 (23): 2205–15. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.050255
40. Szarek M., Bhatt D.L., Steg Ph.G., et al. Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a randomized SOLOIST-WHF trial. Ann Intern Med. 2021; 174 (8): 1065–72. DOI: https://doi.org/10.7326/M21-0651
41. Kurochkina O.N., Baranov A.V., Sazhina A.S., Bogomolov A.N. Organizing medical care for patients with chronic heart failure in Russia regions with a low population density. Profilakticheskaya meditsina [Preventive Medicine]. 2023; 26 (5): 101–8. DOI: https://doi.org/10.17116/profmed202326051101 (in Russian)
42. Kurochkina O.N., Baranov A.V., Sazhina A.S., Bogomolov A.N. Modern methods of treatment of elderly patients with chronic heart failure: a literature review. Farmateka [Pharmateca]. 2023; 30 (1–2): 94–9. DOI: https://doi.org/10.18565/pharmateca.2023.1-2.94-99 (in Russian)
43. Heerspink H.J.L., Stefánsson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–46. DOI: https://doi.org/10.1056/NEJMoa2024816
44. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022; 388: 117–27. DOI: https://doi.org/10.1056/NEJMoa2204233
45. Baigent C., Emberson J., Haynes R., et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400: 1788–801. DOI: https://doi.org/10.1016/S0140-6736(22)02074-8
46. Rena G., Lang C.C. Repurposing metformin for cardiovascular disease. Circulation. 2018; 137 (5): 422–24. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.031735
47. Varjabedian L., Bourji M., Pourafkari L., Nader N.D. Cardioprotection by metformin: beneficial effects beyond glucose reduction. Am J Cardiovasc Drugs. 2018; 18 (3): 181–93. DOI: https://doi.org/10.1007/s40256-018-0266-3
48. Leonova M.V. Metformin prevents the development of atrial fibrillation. Farmateka [Pharmateca]. 2024; (2): 60–4. DOI: https://doi.org/10.18565/pharmateca.2024.2.60-64 (in Russian)
49. Adler A.L. UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes. Diabet Med. 2008; 2: 41–6. DOI: https://doi.org/10.1111/j.1464-5491.2008.02498.x
50. Rosenstock J., Kahn S.E., Johansen O.E., et al.; The CAROLINA Investigators: Effect of linagliptin vs limepiride on major adverse cardiovascular outcomes in patients with type2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019; 322 (12): 1155–66. DOI: https://doi.org/10.1001/jama.2019.13772
51. Liu D., Jin B., Chen W., et al. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2019; 20: 15. DOI: https://doi.org/10.1186/s40360-019-0293-y
52. Salukhov V.V., Kovalevskaya E.A. Rethinking the role of pioglitazone in modern diabetology from the perspective of its cardiorenoprotective properties. Meditsinskiy sovet [Medical Council]. 2022; 16 (10): 10–21. DOI: https://doi.org/10.21518/2079-701X-2022-16-10-10-21 (in Russian)
53. Holman R.R., Coleman R.L., Chan J.C.N., et al.; ACE Study Group. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5 (11): 877–86. DOI: https://doi.org/10.1016/S2213-8587(17)30309-1
54. Doenst T., Haverich A., Serruys P., et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol. 2019; 73 (8): 964–76. DOI: https://doi.org/10.1016/j.jacc.2018.11.053 PMID: 30819365.
55. Farkoukh M.E., Domanski M., Sleeper L.A., et al. Multivessel revascularization strategies in patients with diabetes mellitus. N Engl J Med. 2012; 367: 2375–84.
56. BARI 2D Study Group; Fry R.L., August P., Brooks M.M., et al. Randomized trial of treatments for type 2 diabetes mellitus and coronary artery disease. N Engl J Med. 2009; 360: 2503–15.
57. Jaiswal V., Sattar Y., Ang S.P., et al. Long-term outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease: a meta-analysis. Int J Cardiol Heart Vasc. 2023; 46 (1): 101185. DOI: https://doi.org/10.1016/j.ijcha.2023.101185
58. Ahmed A., Varghese K.S., Fusco P.J., et al. Coronary revascularization in patients with diabetes: a meta-analysis of randomized controlled trials and propensity-matched studies. Innovations (Phila). 2023; 18 (1): 29–40. DOI: https://doi.org/10.1177/15569845221143420
59. Ostrominski J.W., Boden W.E. Defining the optimal approach to revascularization in chronic coronary syndrome patients with diabetes and multivessel disease: is our equipoise evidence-based? Int J Cardiol Heart Vasc. 2023; 46: 101200. DOI: https://doi.org/10.1016/j.ijcha.2023.101200

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)